Talk / Overview

There is a big hope that artificial intelligence (AI) will be transformative in drug discovery and development. Progress is fast moving with many AI, machine learning and advance analytics companies regularly approaching Novartis with capabilities that may have the potential to advance research and development. At Novartis, we are developing a standard process for benchmarking that: (i) scientifically evaluates and compares innovation on real tasks important to drug development R&D, (ii) de-risks external engagement by removing the need to provide sensitive data during evaluation, (iii) and reduces internal resources required to engage external partners but also increasing the capacity to scale future collaboration.

Talk / Speakers

Mark Baillie

Director Data Science, Novartis

Talk / Slides

Download the slides for this talk.Download ( PDF, 7607.07 MB)

Talk / Highlights


Novartis benchmarking initiative: making sense of AI through the common task framework

With Mark BailliePublished March 12, 2020

AMLD / Global partners